Skip to content
Faron, etusivu
Careers
For Patients
Contact Information
Search for:
LANGUAGE
English
Suomi
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Analysts
Analysis
Outlook
Share and shareholders
Share information
Share monitor
Shareholders
Management ownership and transactions
Option plans and Warrants
Public offering 2024
Rights Offering 2026
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
Newsroom
Releases and announcements
Blog
Reports and presentations
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Analysts
Analysis
Outlook
Share and shareholders
Share information
Share monitor
Shareholders
Management ownership and transactions
Option plans and Warrants
Public offering 2024
Rights Offering 2026
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
Newsroom
Releases and announcements
Blog
Reports and presentations
Careers
For Patients
Contact Information
Search for:
LANGUAGE
English
Suomi
Blog
General
Faron’s half-year in review: where we stand
Please leave this field empty
Get notified about new Faron blog posts!
Check your inbox or spam folder to confirm your subscription.
Back to top
